Journal Article

Winston et al (Clin Infect Dis 2010;50(6):920–929)

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 51, issue 5, pages 638-638
Published in print September 2010 | ISSN: 1058-4838
Published online September 2010 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/656374
Winston et al (Clin Infect Dis 2010;50(6):920–929)

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In the 15 March 2010 issue of the journal, in the article by Winston et al (Winston A, Duncombe C, Li PCK, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatmentnaive, HIV-1-infected individuals commencing cART? a randomized, controlled study. (Clin Infect Dis 2010; 50:920–929), the report of no potential conflicts of interests on behalf of all authors is incorrect; Alan Winston, John Gill, Patrick Li, David A. Cooper, and Sean Emery have the following potential conflicts of interest:

Alan Winston has received honoraria or research grants from (or has been a consultant or investigator in clinical trials sponsored by) Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Roche, and Pfizer.

John Gill has received honoraria, consultancies, and research grants from (or has been an investigator in clinical trials sponsored by) Abbott, Bristol-Myers Squibb, Thera, Pfizer, Gilead Sciences, GlaxoSmithKline, and Merck Sharp and Dohme.

Patrick Li has been an investigator in clinical trials sponsored by Abbott, Bristol-Myers Squibb, Pfizer, and Merck Sharp and Dohme; has served on advisory boards of Abbott, Pfizer, Janssen- Cilag, and Merck Sharp and Dohme; and had been nominated by Queen Elizabeth Hospital and local professional societies to attend conferences through grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, Roche, IDS, Bayer Schering, and Merck Serono.

David A. Cooper has received honoraria, consultancies, and research grants from (or has been an investigator in clinical trials sponsored by) Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and Merck Sharp and Dohme.

Sean Emery has received honoraria, consultancies, and research grants from (or has been an investigator in clinical trials sponsored by) Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Chiron-Novartis, Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Roche, Tibotec, and Virax Immunotherapeutics

Rebekah L. Puls, Kathy Petoumenos, Steve Kerr, Chris Duncombe, and Simon Taylor-Robinson have no potential conflicts of interest.

The authors regret this error.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.